Guizhou Sanli Pharmaceutical Co Ltd Asset Resilience Ratio
Guizhou Sanli Pharmaceutical Co Ltd asset resilience ratio. Guizhou Sanli Pharmaceutical Co Ltd (603439) has an Asset Resilience Ratio of 2.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Guizhou Sanli Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Guizhou Sanli Pharmaceutical Co Ltd (2021–2024)
Asset resilience ratio of Guizhou Sanli Pharmaceutical Co Ltd from 2021 to 2024. This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Guizhou Sanli Pharmaceutical Co Ltd (603439) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Guizhou Sanli Pharmaceutical Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥59.70 Million | 2.1% |
| Total Liquid Assets | CN¥59.70 Million | 2.10% |
Asset Resilience Insights
- Limited Liquidity: Guizhou Sanli Pharmaceutical Co Ltd maintains only 2.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guizhou Sanli Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guizhou Sanli Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Guizhou Sanli Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2021–2024)
Guizhou Sanli Pharmaceutical Co Ltd asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Guizhou Sanli Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.72% | CN¥22.95 Million ≈ $3.36 Million |
CN¥3.19 Billion ≈ $467.11 Million |
-1.04pp |
| 2023-12-31 | 1.76% | CN¥51.50 Million ≈ $7.54 Million |
CN¥2.92 Billion ≈ $427.35 Million |
-1.53pp |
| 2022-12-31 | 3.30% | CN¥59.91 Million ≈ $8.77 Million |
CN¥1.82 Billion ≈ $265.83 Million |
-3.68pp |
| 2021-12-31 | 6.98% | CN¥98.00 Million ≈ $14.34 Million |
CN¥1.40 Billion ≈ $205.59 Million |
-- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more